Kevin Bodker, DO

I’m a hockey player, but I’m playing doctor today. Fellow of the bean team

[Kevin Bodker, DO @BodkerKevin]

A basic solution for a complex problem: does treatment of... : Current Opinion in Nephrology and Hypertension https://t.co/5GJjRhm2fh

[NEJM @NEJM]

A 70-year-old man undergoing cholangioscopy to evaluate dilatation of the common bile duct was found to have flatworms in his biliary tract (shown in a video). Read the full clinical case: https://t.co/OK4X48EOne

[Kevin Bodker, DO @BodkerKevin]

@kidney_boy I found the bicarb supplementation in renal transplant Lancet study pretty important

[Kevin Bodker, DO @BodkerKevin]

@jfnephlolz Not justifying it, but I think some view it as "doing something." It can feel like we have little to offer when CKD is progressing despite RAAS blockade, SGLT2i, etc. Addition of sodium bicarb tabs may fall into a similar category (but more controversial)

[Kevin Bodker, DO @BodkerKevin]

POCUS exam of the IJ is simple and may provide useful information, particularly for those with with limited experience or for patients with challenging body habitus. I loved this study and wanted to try my hand at infographic (feedback welcome). #Medtwitter #nephtwitter #POCUS

[Kevin Bodker, DO @BodkerKevin]

@NephCrit_NM @kidney_boy @lambchopsMD BICAR-ICU2 is underway specifically in the AKI 2-3 group. I did grand rounds on this and I agree it’s about the only “good” data out there. I also agree with @kidney_boy that NNT of 6 to avoid HD and similar to avoid death may need to be viewed cautiously

[Hugo Diniz, MD 🇵🇹 🇪🇺 @HDiniz_]

Zirconium works in AKI induced HyperK+!
- better resolution of HyperK+
- less relapse
- less need of RRT
#encontrorenal #ERenal23

[Kevin Bodker, DO @BodkerKevin]

@fperrywilson @NephJC @kidney_boy @renal_911 Darn, I missed that one! Good call

[Kevin Bodker, DO @BodkerKevin]

Giving last minute grand rounds today and this is my final slide. Anything else I should add?

@NephJC @kidney_boy @renal_911

#nephrology #nephtwitter #MedTwitter #nephfellow #controversialtopics #firsttweet

[Kevin Bodker, DO @BodkerKevin]

The most interesting point from review of SGLT2i trials, imo, is the correlation between those with a GFR drop after initiations and improved CV and HF outcomes (DAPA-HF). Regardless, the nephrologist in me dies a little on the inside when it happens. #nephtwitter #flozinator

[Kevin Bodker, DO @BodkerKevin]

Grand rounds done (on SGLT2i data). No breaking of glass necessary. Turns out the only the only think the -flozins can’t do is lose. Brief mention of GLP1s in CKD, getting everyone excited for FLOW trial readout in ‘24. Will it be another game changer?

[Kevin Bodker, DO @BodkerKevin]

@nepherson @NephJC @kidney_boy @renal_911 Any of these topics are sure to drum up debate, heated and long. Sure to fill any empty time and overshadow everything I’ve said prior. Not a true device, just a joke